We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+19.19%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$783M
AUM Growth
+$36.9M
Cap. Flow
-$49.7M
Cap. Flow %
-6.35%
Top 10 Hldgs %
34.67%
Holding
106
New
16
Increased
38
Reduced
39
Closed
13

Top Buys

Rank Stock Value
1
TFX icon
Teleflex
TFX
+$22.4M
2
KROS icon
Keros Therapeutics
KROS
+$11M
3
SYK icon
Stryker
SYK
+$9.66M
4
RCUS icon
Arcus Biosciences
RCUS
+$9.62M
5
DGX icon
Quest Diagnostics
DGX
+$8.21M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$16M
2
ELV icon
Elevance Health
ELV
+$15M
3
HUM icon
Humana
HUM
+$11.2M
4
COR icon
Cencora
COR
+$8.56M
5
THC icon
Tenet Healthcare
THC
+$8.34M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELAN icon
76
Elanco Animal Health
ELAN
$11.1B
$1.88M 0.24%
127,812
+1,770
+1% +$24.7K
IRWD icon
77
Ironwood Pharmaceuticals
IRWD
$714M
$1.88M 0.24%
455,477
-420,791
-48% -$2.26M
NARI
78
DELISTED
Inari Medical, Inc. Common Stock
NARI
$1.83M 0.23%
44,301
-151,266
-77% -$7.26M
NAMS icon
79
NewAmsterdam Pharma
NAMS
$3.33B
$1.75M 0.22%
105,334
-30,042
-22% -$520K
LUNG icon
80
Pulmonx
LUNG
$98.4M
$1.71M 0.22%
+206,444
New +$1.49M
ETON icon
81
Eton Pharmaceutcials
ETON
$1.14B
$1.56M 0.2%
260,226
+7,029
+3% +$29.7K
ESPR
82
DELISTED
Esperion Therapeutics
ESPR
$1.49M 0.19%
903,140
-241,506
-21% -$488K
CLYM
83
Climb Bio
CLYM
$827M
$1.42M 0.18%
+278,775
New +$1.97M
TKNO icon
84
Alpha Teknova
TKNO
$397M
$1.21M 0.16%
251,026
-45,626
-15% -$168K
AKYA
85
DELISTED
Akoya BioSciences
AKYA
$1.02M 0.13%
376,131
+595
+0.2% +$1.45K
ARDX icon
86
Ardelyx
ARDX
$1.03B
$875K 0.11%
126,940
-23,252
-15% -$137K
ENTX icon
87
Entera Bio
ENTX
$138M
$781K 0.1%
411,076
+9,558
+2% +$17K
RVPH
88
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
$738K 0.09%
25,610
+380
+2% +$8.44K
XFOR icon
89
X4 Pharmaceuticals
XFOR
$425M
$548K 0.07%
27,291
+404
+2% +$8.43K
FOCL
90
EDAP TMS S.A.
FOCL
$178M
$395K 0.05%
+154,832
New +$634K
YARW
91
Yarrow Bioscience, Inc. Common Stock
YARW
$114M
$382K 0.05%
4,059
-2,845
-41% -$270K
XERS icon
92
Xeris Biopharma Holdings
XERS
$1.55B
$292K 0.04%
102,393
+1,563
+2% +$4.01K
NSPR icon
93
InspireMD
NSPR
$40.3M
$279K 0.04%
+104,081
New +$284K
BMY icon
94
Bristol-Myers Squibb
BMY
$130B
– –
-200,000
Closed -$8.31M
COR icon
95
Cencora
COR
$60B
– –
-38,014
Closed -$8.56M
ELV icon
96
Elevance Health
ELV
$86.6B
– –
-27,751
Closed -$15M
FTRE icon
97
Fortrea Holdings
FTRE
$1.74B
– –
-152,769
Closed -$3.57M
HAE icon
98
Haemonetics
HAE
$4.16B
– –
-76,079
Closed -$6.29M
HUM icon
99
Humana
HUM
$46.7B
– –
-30,037
Closed -$11.2M
IONS icon
100
Ionis Pharmaceuticals
IONS
$9.39B
– –
-161,705
Closed -$7.71M
1 2 3
4
5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q3 2024 Portfolio in Review

As of Q3 2024, Parkman Healthcare Partners held 106 positions worth $783M, up 4.9% from $747M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Parkman Healthcare Partners withdrew a net $49.7M in Q3 2024, closing 13 positions and reducing 39 holdings. Its most notable exit was Elevance Health, an estimated $15M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Industrials.

Against the trend, Parkman Healthcare Partners opened a new position in Teleflex worth $23.8M.

  • Parkman Healthcare Partners's largest Q3 2024 buy was Teleflex: 96,144 shares worth $23.8M.
  • Parkman Healthcare Partners added most to Keros Therapeutics in Q3 2024, an estimated $11M increase.
  • Parkman Healthcare Partners's biggest Q3 2024 reduction was United Therapeutics, cutting an estimated $16M.
  • Parkman Healthcare Partners fully exited Elevance Health in Q3 2024, selling an estimated $15M.
  • Parkman Healthcare Partners's ten largest holdings make up 35% of its $783M portfolio in Q3 2024.
  • Parkman Healthcare Partners opened 16 new positions and closed 13 in Q3 2024.
  • Parkman Healthcare Partners's portfolio value rose 4.9% quarter-over-quarter to $783M.

Based on Parkman Healthcare Partners's 13F filing for Q3 2024, filed 14 Nov 2024.